Alcohol Use Disorder (AUD): Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Alcohol use disorder (AUD) is a chronic, relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It is a "brain disease" model condition in the addiction neuroscience literature — involving compulsive substance seeking and use, loss of control over intake, and a negative emotional state when the substance is unavailable (Koob & Volkow, Lancet Psychiatry 2016, PMID: 27475769; Volkow, Koob & McLellan, NEJM 2016, PMID: 26816013). The DSM-5 (American Psychiatric Association, 2013) merged the former DSM-IV categories of "alcohol abuse" and "alcohol dependence" into a single diagnosis, Alcohol Use Disorder, scored on a continuum of mild (2–3 symptoms), moderate (4–5 symptoms), or severe (≥6 symptoms) from an 11-item symptom list spanning impaired control, social impairment, risky use, and pharmacological criteria (tolerance, withdrawal).

Key identifiers: | Resource | Identifier | Notes | |---|---|---| | OMIM | #103780 "Alcohol Dependence" (phenotype MIM); related gene loci ADH1B (103720), ALDH2 (100650) | Number-sign entry reflecting polygenic susceptibility (multiple genes/loci) rather than a single-gene Mendelian disorder | | ICD-11 | 6C40 "Disorders due to use of alcohol" (parent), with children 6C40.0 (episode of harmful use), 6C40.1 (harmful pattern of use), 6C40.2 (alcohol dependence), plus 6C40.3–6C40.7 (alcohol intoxication, withdrawal, withdrawal delirium, alcohol-induced psychotic/mood/anxiety disorder) (Saunders, Alcohol Clin Exp Res 2019, PMID: 31194891; Poznyak et al., PMC9881115) | | ICD-10-CM | F10.- "Alcohol related disorders" (e.g., F10.20 alcohol dependence, uncomplicated; F10.10 alcohol abuse) | | MeSH | Alcoholism (D000437); related headings "Alcohol-Related Disorders" (D000431) and "Binge Drinking" (D058188) | | MONDO | Mondo harmonizes AUD with OMIM #103780 and ICD-11 6C40; the exact MONDO CURIE was not confirmed against a live ontology browser in this research pass and should be verified via the Monarch Initiative / OLS4 MONDO browser before use in curation, rather than asserted here | | Orphanet | Not applicable — AUD is a common complex disorder, outside Orphanet's rare-disease scope | | GARD/NORD | Not applicable (common disorder) |

Synonyms/alternative names: Alcoholism; alcohol dependence; alcohol addiction; alcohol abuse (older, narrower DSM-IV term now subsumed); "problematic alcohol use" (the phenotype label commonly used in genetics literature to combine clinical AUD diagnoses with the AUDIT-C/AUDIT screening-based phenotype).

Evidence basis. Most of the epidemiological and diagnostic-criteria literature is derived from aggregated population-level survey data (e.g., NESARC-III, NSDUH, UK Biobank) rather than individual EHR chart review, supplemented by large-scale biobank/EHR-linked genomic cohorts (Million Veteran Program, UK Biobank, FinnGen, Psychiatric Genomics Consortium) for genetic association analyses.

2. Etiology

Disease Causal Factors

AUD is a multifactorial, gene-environment disorder. No single causal lesion exists; risk emerges from the additive and interactive effects of many common genetic variants of small individual effect, combined with environmental exposure (access to alcohol, early-life drinking onset, stress, trauma, peer/family use) and repeated pharmacological exposure to ethanol producing durable neuroadaptation (see Mechanism, §6).

Genetic Risk Factors

Twin/family heritability: Genetic factors account for an estimated 40–60% of variance in liability to alcohol dependence (OMIM #103780, summarizing family/twin/adoption literature). A twin-and-adoption meta-analysis (Verhulst, Neale & Kendler, Psychol Med 2015, PMID: 25066582) is the standard heritability reference. Recent longitudinal twin work models AUD symptom liability as more heritable (~36%) than symptom count (~22%) or categorical diagnosis (~14%), with genetic influence on most DSM-5 criteria (except craving) substantially overlapping across symptoms (per search of PMC13092882 / ScienceDirect twin-genetics literature).
Alcohol-metabolizing enzyme variants (largest documented single-locus effects, protective/predisposing):
ADH1B (alcohol dehydrogenase 1B; HGNC:249; OMIM 103720) — the fast-metabolizing variant rs1229984 (His48Arg, also called ADH1B2) accelerates ethanol→acetaldehyde conversion, causing an aversive acetaldehyde buildup and flushing reaction that is strongly protective against AUD (odds ratios for protection commonly reported 1.2–1.8 per allele; the variant is one of the most replicated genome-wide-significant hits across alcohol-phenotype GWAS).
ALDH2 (aldehyde dehydrogenase 2, mitochondrial; HGNC:404) — the East Asian–specific loss-of-function variant rs671 (Glu504Lys, ALDH2*2) impairs acetaldehyde clearance, producing the "Asian flushing" reaction; it is the single largest-effect protective variant known for alcohol consumption/AUD in East Asian populations (Science Advances 2023/2024 genotype-stratified Japanese GWAS; PMID for Edenberg's foundational review: 17718403).
ADH1C, ADH4 — additional class I/II ADH cluster genes on chr4q23 in linkage disequilibrium with ADH1B, contributing modestly.
Reward/neurotransmission genes:
GABRA2 (GABA-A receptor alpha-2 subunit; HGNC:4083) — one of the earliest and most replicated non-metabolic AUD/alcohol-dependence association genes (Edenberg et al., Am J Hum Genet 2004, PMID: 15024690), implicating GABAergic inhibitory tone in dependence risk.
KLB (beta-klotho, co-receptor for FGF21; chr4q14) — index SNP rs11940694 associated with AUDIT total score/alcohol consumption across multiple large GWAS; mechanistically links to a liver–brain FGF21 endocrine axis regulating alcohol preference.
GCKR (glucokinase regulator) — replicated locus linking alcohol consumption to glucose/lipid metabolism pathways.
OPRM1 (mu-opioid receptor; HGNC:8156) — the rs1799971 (A118G) variant has been extensively studied as a moderator of naltrexone treatment response (pharmacogenomic significance; see §12) though large prospective genotype-stratified trials have failed to confirm a clinically actionable effect.
Large-scale multi-ancestry GWAS: Zhou et al. (Nature Medicine, 2023; cross-ancestry meta-analysis of 1,079,947 individuals — European N=903,147, African N=122,571, Latin American N=38,962, East Asian N=13,551, South Asian N=1,716) identified 110 independent risk variants for "problematic alcohol use," with fine-mapping and gene-expression/chromatin-interaction prioritization implicating additional brain-expressed genes beyond the classical metabolic loci; a related multi-ancestry cross-disorder pleiotropy analysis (Nature Mental Health, 2024) further links AUD risk loci to psychiatric cross-disorder liability.
Polygenic architecture: As with most psychiatric traits, common-variant SNP heritability is substantial but individual locus effects (outside ADH1B/ALDH2) are small (odds ratios typically 1.03–1.10), consistent with a highly polygenic trait amenable to polygenic risk scoring but not single-gene diagnostic testing.
Modifier/pleiotropic genes: Genome-wide genetic correlations link AUD risk to major depressive disorder, ADHD, schizophrenia, and other substance use disorders (shared liability/"externalizing" and "internalizing" genetic factors), consistent with the high phenotypic psychiatric comorbidity described in §5/§11.

Environmental Risk Factors

Early age of drinking onset; heavy episodic ("binge") drinking patterns; chronic stress and adverse childhood experiences/trauma (including PTSD); family/peer alcohol use and permissive social norms; low socioeconomic status and unemployment; occupational alcohol access; psychiatric comorbidity (self-medication hypothesis); male sex (higher prevalence, though the gap is narrowing); comorbid nicotine/other substance use; alcohol outlet density and marketing exposure; and — per Global Burden of Disease trend analyses — rising per-capita alcohol availability in medium-to-high sociodemographic-index regions, particularly pronounced in Eastern Europe (Frontiers in Public Health 2025 GBD working-age trend analysis, PMC12336152).

Protective Factors

Genetic: ADH1B2 (rs1229984) and ALDH22 (rs671), as above — the clearest examples of genetically protective alleles for any common psychiatric/behavioral disorder.
Environmental: Religious/cultural abstinence norms, strong family cohesion and monitoring, delayed drinking-onset policies (minimum legal drinking age), alcohol taxation/pricing policy, restricted outlet density, and access to early intervention/brief counseling.

Gene-Environment Interactions

The genotype-stratified 2023/2024 Japanese GWAS (175,672 individuals; Science Advances) is a landmark G×E-adjacent design: because ALDH2 rs671 genotype strongly gates the physiological consequence of drinking, stratifying by rs671 genotype revealed genome-wide-significant interaction signals at several loci (in addition to the three loci significant in wild-type homozygotes: GCKR, KLB, ADH1B), demonstrating that genetic background modulates how strongly environmental alcohol exposure translates into consumption/AUD risk. More broadly, stressful environments and early-life adversity are hypothesized to interact with GABAergic/HPA-axis genetic variation to potentiate AUD risk (a widely cited but still maturing area of human GxE research, largely built on candidate-gene rather than genome-wide interaction studies to date).

3. Phenotypes

AUD phenotypes span behavioral/psychiatric symptoms (the DSM-5 diagnostic criteria), physiological withdrawal/tolerance signs, and downstream organ-system complications from chronic use.

Core DSM-5 diagnostic symptom domains (11 criteria, ≥2 required within 12 months for diagnosis)

Drinking more/longer than intended (impaired control)
Persistent desire or unsuccessful efforts to cut down
Great deal of time spent obtaining/using/recovering from alcohol
Craving — strong desire/urge to drink
Failure to fulfill major role obligations (social impairment)
Continued use despite social/interpersonal problems caused by alcohol
Important activities given up/reduced because of drinking
Recurrent use in physically hazardous situations (risky use)
Continued use despite knowledge of physical/psychological problems caused by alcohol
Tolerance — need for markedly increased amounts for the same effect
Withdrawal — characteristic withdrawal syndrome, or use to relieve/avoid withdrawal

Acute intoxication phenotypes

Slurred speech, incoordination, unsteady gait, nystagmus, impaired attention/memory, stupor/coma at high blood alcohol concentration; behavioral disinhibition, mood lability. - Suggested HPO: HP:0001350 (Slurred speech), HP:0001288 (Gait disturbance), HP:0000639 (Nystagmus), HP:0001269 (Abnormality of the nervous system — parent term where specific descendants are lacking)

Alcohol withdrawal syndrome (onset hours after cessation in a physiologically dependent individual)

Minor withdrawal (6–24h): tremor, anxiety, headache, GI upset, insomnia, autonomic hyperactivity (tachycardia, diaphoresis, hypertension). Suggested HPO: HP:0002378 (Tremor)/HP:0030955, HP:0000738 (Anxiety), HP:0002099 (Tachypnea, if relevant), HP:0100543 (Cognitive impairment).
Withdrawal seizures: typically generalized tonic-clonic, occurring within the first 12–48h. Suggested HPO: HP:0002069 (Generalized tonic-clonic seizure).
Alcohol withdrawal delirium (Delirium Tremens): the most severe manifestation, occurring 24–72h (occasionally later) after last drink in a minority of patients with withdrawal seizures; fluctuating consciousness disturbance, profound disorientation/confusion, visual/tactile hallucinations, fever, marked tachycardia, diaphoresis, hypertension (StatPearls NBK441882; PMC11069634 DT clinical review). Untreated mortality historically up to 15–20%, now much lower with benzodiazepine-based management. Suggested HPO: HP:0000726 (Dementia — imprecise), HP:0031466 or general HP:0000708 (Behavioral abnormality); note HPO lacks a precise "delirium" term in common use — best modeled via MONDO's own ICD-11 6C40.4 child term rather than forced HPO mapping.

Cognitive/psychiatric phenotypes

Impaired executive function, working memory, and decision-making (frontostriatal dysfunction); depressed mood; anxiety; irritability; sleep disturbance; anhedonia during protracted abstinence (part of the "negative affect" stage of the addiction cycle — see Mechanism). Suggested HPO: HP:0000726, HP:0000716 (Depressivity), HP:0000739 (Anxiety) mapped as available, HP:0002360 (Sleep disturbance).

End-organ complication phenotypes (chronic, downstream)

Hepatic: steatosis → alcoholic hepatitis → fibrosis → cirrhosis. HP:0001397 (Hepatic steatosis), HP:0001394 (Hepatic fibrosis/Cirrhosis).
Neurological: peripheral neuropathy (HP:0009830), cerebellar ataxia/degeneration (HP:0001251), Wernicke encephalopathy (thiamine-deficiency triad: confusion, ataxia, ophthalmoplegia) and Korsakoff amnestic syndrome, cognitive decline.
Cardiovascular: cardiomyopathy (HP:0001638), hypertension, arrhythmia (atrial fibrillation — "holiday heart").
GI/pancreatic: pancreatitis (HP:0001733), gastritis, esophageal varices.
Psychiatric comorbid conditions: as detailed in §5/§11.

Phenotype characteristics

Onset: Typically emerges in late adolescence to young adulthood (peak initiation age 18–25), though diagnostic threshold crossing (moderate/severe AUD) often occurs later after years of escalating use; late-onset AUD (>40–50 years) is a recognized, often better-prognosis subtype.
Severity: DSM-5 stratifies mild/moderate/severe by symptom count; severity correlates with likelihood of withdrawal complications and treatment resistance.
Progression: Variable — can be chronic-progressive, episodic/relapsing-remitting (the modal pattern, with periods of abstinence/moderation punctuated by relapse), or, in a substantial minority, spontaneously remitting without formal treatment ("natural recovery," more common in milder cases).
Frequency (US NESARC-III): 12-month prevalence of DSM-5 AUD ≈ 13.9%; lifetime prevalence ≈ 29.1% (Grant et al., JAMA Psychiatry 2015, PMID: 26039070).

Quality of Life Impact

AUD is a leading contributor to global disability-adjusted life years (DALYs) among behavioral/substance disorders (Global Burden of Disease). Impacts span occupational/functional impairment, relationship breakdown, legal/financial consequences, and markedly reduced health-related quality of life scores (EQ-5D/SF-36 domains), compounded further once end-organ complications (cirrhosis, neuropathy, cognitive decline) develop.

4. Genetic/Molecular Information

Causal/Major-Effect Genes (complex trait — no monogenic Mendelian cause; these are the largest-effect common-variant loci)

Table (click to expand)

Gene	HGNC	Locus	Variant	Effect
ADH1B	HGNC:249	4q23	rs1229984 (His48Arg)	Protective — fast ethanol oxidation → acetaldehyde buildup
ALDH2	HGNC:404	12q24.12	rs671 (Glu504Lys)	Strongly protective (East Asian populations) — impaired acetaldehyde clearance
ADH1C	HGNC:251	4q23	in LD with ADH1B	Modest, population-dependent
GABRA2	HGNC:4083	4p12	multiple intronic/regulatory SNPs	Risk — GABAergic inhibitory signaling
KLB	HGNC:24578	4q14.1	rs11940694	Risk — FGF21 co-receptor, consumption phenotype
GCKR	HGNC:4196	2p23.3	rs1260326 (and others)	Risk — metabolic pathway pleiotropy
OPRM1	HGNC:8156	6q25.2	rs1799971 (A118G)	Modifier of opioidergic reward signaling; naltrexone response modifier (contested)

Pathogenic Variants / Classification

AUD is not classified under ACMG/AMP pathogenicity tiers (pathogenic/likely pathogenic/VUS) because it is a polygenic complex trait, not a monogenic Mendelian condition; ClinVar does not carry AUD-specific variant classifications. Variant-level evidence instead comes from GWAS association statistics (odds ratios, p-values, fine-mapping posterior probabilities) rather than clinical variant curation. - Allele frequency: ADH1B2 (rs1229984) is common in East Asian (~70%) populations and less common in European (~5–10%) and rare in African populations; ALDH22 (rs671) allele frequency is ~30–50% in East Asian populations and essentially absent elsewhere (gnomAD, 1000 Genomes population panels). - Origin: Germline, common polymorphisms (not somatic). - Functional consequence: ADH1B2 = gain-of-function (faster catalytic turnover) in ethanol oxidation; ALDH22 = dominant-negative loss-of-function in the tetrameric mitochondrial ALDH2 enzyme (heterozygotes show substantial enzyme inactivation due to the dominant-negative effect of the mutant subunit within the homotetramer).

Modifier Genes

Genes in the "externalizing" and psychiatric cross-disorder polygenic factors (e.g., loci shared with ADHD, MDD, schizophrenia via genetic correlation) act as risk modifiers rather than primary causal loci; DRD2, CHRM2, SLC6A4 (serotonin transporter) have candidate-gene literature of variable replication.

Epigenetic Information

Chronic alcohol exposure is associated with genome-wide DNA methylation changes in blood and brain tissue, particularly at genes involved in immune signaling, neurodevelopment, and ALDH2/ADH loci themselves; histone modification changes (e.g., altered H3K4/H3K9 methylation, histone acetylation via HDAC inhibition by acetaldehyde metabolites) in reward-circuit brain regions have been implicated in the maintenance of compulsive drinking behavior in preclinical models. Human epigenome-wide association studies (EWAS) of AUD have identified differentially methylated regions overlapping known GWAS loci (JCI review of AUD human genetics/epigenetics, 2023–2024, JCI 172885).

Chromosomal Abnormalities

Not a feature of AUD — no recurrent aneuploidy, translocation, or CNV syndrome is causally implicated; AUD is excluded from chromosomal-abnormality databases (DECIPHER, ECARUCA) as it is not a genomic disorder in that sense.

5. Environmental Information

Environmental/toxicological factor: Ethanol (CHEBI:16236) itself is the causal exposure — a CNS depressant and hepatotoxin metabolized primarily via ADH→acetaldehyde (CHEBI:15343, a Group 1 IARC carcinogen)→ALDH→acetate.
Lifestyle factors: Binge drinking pattern (≥4/5 drinks for women/men in ~2 hours), drinking frequency and quantity, co-use with nicotine/other substances, diet (poor nutrition, thiamine deficiency risk), sedentary behavior, sleep disruption.
Infectious agents: Not a primary etiological factor for AUD itself, though chronic AUD is a major risk factor for infection susceptibility (immune suppression) and complicates management of infections such as hepatitis B/C (shared risk behaviors) and tuberculosis reactivation.
Socioenvironmental/structural factors: Alcohol marketing and outlet density, price/taxation policy, occupational exposure (hospitality/service industries), cultural/religious drinking norms, and adverse childhood experiences (ACEs)/trauma exposure, which is one of the most robust non-genetic risk amplifiers documented in the epidemiological literature.

6. Mechanism / Pathophysiology

AUD pathophysiology is best conceptualized (Koob & Volkow's addiction-cycle model, Lancet Psychiatry 2016, PMID: 27475769) as progression through three recurring, neuroadapting stages: binge/intoxication → withdrawal/negative affect → preoccupation/anticipation (craving), each mapped to a distinct but interconnected brain circuit.

Molecular pathways and neurotransmitter systems

GABAergic potentiation (acute): Ethanol acutely potentiates GABA-A receptor–mediated inhibitory neurotransmission (positive allosteric modulation), producing sedative/anxiolytic acute effects. Ventral tegmental area (VTA) GABA interneurons are implicated in alcohol reward: ethanol increases VTA dopamine neuron firing partly via inhibition of GABA release onto dopaminergic neurons (disinhibition mechanism) (PMC5605989; troscriptions/GABA review synthesis; Knowledge atlas bibliometric review PMC9411946).
Glutamatergic suppression (acute) → glutamatergic hyperexcitability (chronic): Acute ethanol inhibits NMDA receptor–mediated glutamatergic transmission; chronic exposure produces a compensatory upregulation/sensitization of NMDA and other glutamate receptor signaling, so that upon alcohol cessation the CNS is left in a hyperglutamatergic, hyperexcitable state — the principal mechanism underlying withdrawal hyperexcitability, tremor, and seizures (PMC4407613, "Targeting glutamate uptake to treat AUD"; PMC9411946).
Mesolimbic dopamine system: Acute alcohol increases dopamine release in the nucleus accumbens via VTA disinhibition, mediating acute reward. With repeated/chronic exposure, there is a reduction in baseline mesolimbic dopaminergic tone during withdrawal/abstinence — the "reward deficit" that drives negative affect and relapse vulnerability (Koob, Curr Top Behav Neurosci 2013, PMID: 24273570; MDPI AUD Neurobiology and Therapeutics review, 2022).
Opioidergic system: Ethanol triggers endogenous opioid (beta-endorphin) release, which stimulates VTA dopamine neurons via mu-opioid receptor (OPRM1)–mediated disinhibition of GABAergic interneurons — the mechanistic basis for opioid-antagonist pharmacotherapy (naltrexone; see §12).
HPA axis and extended amygdala stress systems: Chronic alcohol exposure dysregulates corticotropin-releasing factor (CRF) signaling in the central nucleus of the amygdala and bed nucleus of the stria terminalis, producing a sensitized stress response that drives negative-affect-motivated drinking during withdrawal — a key target of experimental CRF1-antagonist and related pharmacotherapies.

Cellular processes

Neuroinflammation (microglial activation via TLR4 signaling in response to ethanol/acetaldehyde), oxidative stress, mitochondrial dysfunction (notably in hepatocytes, driving alcoholic liver disease — feeds into the dismech hepatic_steatosis_lipotoxicity and drug_induced_liver_injury-adjacent mechanism space), synaptic pruning/remodeling in prefrontal cortex reducing top-down inhibitory control over subcortical reward circuitry, and apoptosis of thiamine-dependent neurons in Wernicke-Korsakoff pathology.

Protein dysfunction / biochemical abnormalities

Enzymatic: ADH/ALDH functional variation (see §4) directly alters the toxic acetaldehyde intermediate's accumulation — the central biochemical determinant of both flushing reactions and long-term carcinogenic/hepatotoxic risk.
Receptor-level: NMDA receptor subunit composition shifts (increased GluN2B expression) with chronic exposure; GABA-A receptor subunit composition changes (e.g., altered alpha4/delta subunit expression) underlying tolerance.

Metabolic changes

Ethanol oxidation consumes NAD+ (shifting hepatocyte NADH:NAD+ ratio), promoting lipogenesis and inhibiting fatty acid oxidation and gluconeogenesis — the direct biochemical driver of hepatic steatosis; chronic heavy drinking also produces caloric substitution/malnutrition and thiamine (vitamin B1) deficiency, precipitating Wernicke encephalopathy.

Immune system involvement

Chronic alcohol exposure activates innate immune signaling (TLR4/NF-kB pathway) in both liver (Kupffer cells) and brain (microglia), producing a pro-inflammatory state that contributes both to alcoholic liver disease progression and to neuroinflammation-driven negative affect/craving.

Tissue damage mechanisms

Oxidative stress (reactive oxygen species from CYP2E1-mediated ethanol metabolism, induced with chronic heavy use), acetaldehyde protein/DNA adduct formation (carcinogenic mechanism), and progressive fibrosis (activated hepatic stellate cells — connects directly to the dismech fibrotic_response module architecture) in the liver; excitotoxic and oxidative neuronal injury in the CNS.

Molecular profiling

Transcriptomics: Postmortem and preclinical brain expression studies (GEO, GTEx-adjacent AUD brain expression datasets) show altered expression of genes in myelination, synaptic transmission, and immune pathways in prefrontal cortex of individuals with AUD.
Proteomics/metabolomics: Serum biomarkers of chronic heavy use include elevated carbohydrate-deficient transferrin (CDT), phosphatidylethanol (PEth — a direct ethanol metabolite biomarker with high specificity), and gamma-glutamyl transferase (GGT).
Single-cell/spatial: Emerging single-nucleus RNA-seq studies of postmortem AUD prefrontal cortex and amygdala tissue (Human Cell Atlas-adjacent efforts) are beginning to resolve cell-type-specific transcriptional signatures (microglial activation states, oligodendrocyte/myelination changes) associated with chronic alcohol exposure (PMC11566292, "Modeling Brain Gene Expression in AUD with Genetic Animal Models," 2024).

Suggested ontology terms

GO (biological process): GO:0035249 (synaptic transmission, glutamatergic); GO:0051932 (synaptic transmission, GABAergic); GO:0007268 (chemical synaptic transmission); GO:0006066 (alcohol metabolic process); GO:0006979 (response to oxidative stress); GO:0032496 (response to lipopolysaccharide, for neuroinflammatory signaling).
CL (cell types): dopaminergic neuron (VTA), GABAergic interneuron, hepatic stellate cell, Kupffer cell, microglial cell — exact CL CURIEs should be confirmed via OAK/OLS before KB entry.
CHEBI: ethanol (CHEBI:16236), acetaldehyde (CHEBI:15343), acetate (CHEBI:30089).

7. Anatomical Structures Affected

Organ level

Primary: Brain (mesocorticolimbic reward circuitry) and liver (primary site of metabolism and chronic toxic injury).
Secondary/complication organs: Pancreas (pancreatitis), heart (cardiomyopathy, arrhythmia), peripheral nervous system (neuropathy), GI tract (gastritis, esophageal varices from portal hypertension), immune system (impaired host defense).
Body systems: Nervous system (central and peripheral), hepatobiliary system, cardiovascular system, digestive system, endocrine system (HPA axis dysregulation).

Tissue/cell level

Neurons (dopaminergic VTA neurons, GABAergic interneurons, glutamatergic pyramidal neurons of prefrontal cortex), microglia, astrocytes; hepatocytes and hepatic stellate cells; pancreatic acinar cells; cardiomyocytes.

Subcellular level

Mitochondria (site of ALDH2 activity and oxidative-stress generation), synaptic membrane receptor complexes (GABA-A, NMDA receptor), endoplasmic reticulum (unfolded protein response in hepatocytes under ethanol-metabolic stress).

Localization (brain circuitry — key nodes)

Ventral tegmental area (VTA) — dopaminergic cell bodies
Nucleus accumbens (ventral striatum) — reward/binge-intoxication node
Central nucleus of the amygdala / extended amygdala — withdrawal/negative-affect node
Prefrontal cortex (particularly orbitofrontal and dorsolateral) — preoccupation/craving, impaired executive control
Bed nucleus of the stria terminalis — stress-integration node
Hippocampus — memory/conditioned-cue association with drinking contexts

Suggested UBERON terms (verify exact CURIEs before curation use): ventral tegmental area, nucleus accumbens, amygdala, prefrontal cortex, liver (UBERON:0002107), pancreas, heart.

8. Temporal Development

Onset: Modal initiation of alcohol use in adolescence; problematic use/AUD symptom crossing typically emerges in the late teens to twenties, though clinically significant AUD can be diagnosed at any adult age. Earlier age of drinking onset is itself a well-established risk factor for later AUD severity.
Onset pattern: Typically insidious/gradual escalation over months to years, though acute severe intoxication episodes and withdrawal syndromes are themselves acute events superimposed on the chronic underlying disorder.
Disease stages: Mild/moderate/severe by DSM-5 symptom count; clinically often staged as at-risk/hazardous use → harmful use → dependence, paralleling ICD-11's harmful-pattern-of-use vs. dependence distinction.
Progression rate/course: Highly variable — chronic-relapsing course is most typical, with the majority of individuals cycling through periods of abstinence, moderation, and relapse (NESARC longitudinal follow-up data); a substantial minority (especially milder cases) achieve natural remission without formal treatment.
Duration: Can be lifelong/chronic if untreated, though average time from AUD onset to first treatment contact is often many years (a documented treatment gap).
Remission patterns: Both spontaneous ("maturing out," more common with milder AUD and with life transitions such as marriage/parenthood/employment) and treatment-induced remission occur; formal remission criteria (DSM-5: early remission ≥3 but <12 months, sustained remission ≥12 months without criteria met, except craving) are defined.
Critical periods: Adolescence/young adulthood represents a neurodevelopmental window of heightened vulnerability, as the prefrontal cortex (executive control) matures later than subcortical reward circuitry, and early heavy exposure during this window produces more durable neuroadaptation.

9. Inheritance and Population

Epidemiology

Global prevalence (GBD 2023/2021 estimates): ~111.12 million people worldwide with AUD in 2021 (per Global Burden of Disease modeling reported via Our World in Data/IHME), representing a 14.66% increase in prevalence between 2000 and 2021. Age-standardized incidence, mortality, and DALY rates have generally declined from 1990–2021 even as absolute case counts (and burden in medium-to-high sociodemographic-index regions, especially Eastern Europe) have risen (Frontiers in Public Health 2025, PMC12336152).
US-specific (NESARC-III, DSM-5 criteria): 12-month prevalence 13.9%; lifetime prevalence 29.1% (Grant et al. 2015, PMID: 26039070).

Inheritance pattern

Complex/multifactorial (polygenic) inheritance — not Mendelian. No single gene is necessary or sufficient; risk is conferred by the additive/interactive effect of many common variants (see §4) combined with environmental exposure. - Penetrance: Not applicable in the Mendelian sense; better described via polygenic liability-threshold models, where genetic loading + environmental exposure must exceed a threshold for the clinical phenotype to manifest. - Expressivity: Highly variable — symptom profile, severity, and course differ substantially between individuals with similar genetic loading, reflecting the dominant role of environmental/behavioral exposure. - Genetic anticipation, germline mosaicism, chromosomal founder effects: Not applicable (not a repeat-expansion or single-gene Mendelian disorder). - Founder-effect-like population variation: ALDH22 (rs671) and ADH1B2 (rs1229984) show marked population-specific allele frequency differences (East Asian populations carry much higher frequencies of both protective alleles than European or African populations), producing genuine population-level differences in AUD prevalence and alcohol-flush phenotype that are population-genetic in origin (not classical single-family founder effects). - Consanguinity: Not a relevant risk modifier for a polygenic behavioral trait of this kind. - Carrier frequency: Not applicable (no single causal allele to carry).

Population demographics

Sex ratio: Historically strongly male-predominant (~2:1 to 3:1 male:female in most population surveys), though the gap has been narrowing in recent US/European cohorts, particularly among younger birth cohorts.
Geographic distribution: Highest age-standardized burden concentrated in Eastern Europe and parts of the former Soviet Union; substantial variation globally tied to per-capita alcohol consumption, religious/cultural abstinence norms (lower burden in many Muslim-majority countries), and alcohol policy environments.
Ethnic/ancestry variation: Markedly lower alcohol consumption and AUD prevalence in East Asian populations carrying high frequencies of ALDH22/ADH1B2 protective alleles; Indigenous populations in some regions show elevated AUD burden associated with a complex mix of socioeconomic marginalization, historical trauma, and, in some studies, differing ADH/ALDH allele frequencies.
Age distribution: Prevalence peaks in young adulthood (18–29) and generally declines with age, though a meaningful late-onset subgroup exists.

10. Diagnostics

Clinical tests / laboratory

Direct alcohol biomarkers: Blood alcohol concentration (acute intoxication); phosphatidylethanol (PEth) — a direct, highly specific biomarker of recent heavy alcohol use with a longer detection window (~2–4 weeks) than ethanol itself; ethyl glucuronide (EtG) and ethyl sulfate (EtS) in urine/hair for abstinence monitoring.
Indirect biomarkers: Elevated gamma-glutamyl transferase (GGT), carbohydrate-deficient transferrin (CDT), mean corpuscular volume (MCV, macrocytosis), AST:ALT ratio typically >2 in alcoholic hepatitis (vs. viral hepatitis where ALT>AST).
Imaging: Liver ultrasound/elastography (steatosis, fibrosis staging), brain MRI (cerebellar/cortical atrophy in chronic heavy use, mammillary body changes in Wernicke encephalopathy).
Biopsy/histopathology: Liver biopsy showing steatosis, Mallory-Denk bodies, and neutrophilic infiltration in alcoholic hepatitis; progression to bridging fibrosis/cirrhosis on later biopsy.

Genetic testing

Not part of routine clinical diagnosis — AUD diagnosis is entirely clinical/behavioral (DSM-5/ICD-11 criteria), not confirmed via genetic testing. Research-context genotyping of ADH1B/ALDH2 is occasionally used in pharmacogenomic or population-genetics research contexts (and is directly clinically relevant when disulfiram or disulfiram-like reactions are anticipated), but there is no clinical genetic panel, WGS/WES indication, or GTR-listed diagnostic test for AUD itself.

Clinical diagnostic criteria

DSM-5 (11-criterion symptom count, mild/moderate/severe severity tiers) — the primary US clinical/research diagnostic standard.
ICD-11 (6C40 series) — distinguishes harmful pattern of use from dependence using a somewhat different (narrower, more clinically focused) criteria set than DSM-5, a distinction actively discussed in the nosology literature (Saunders 2019, PMID: 31194891; PMC6899584 critique).
Screening instruments: AUDIT (Alcohol Use Disorders Identification Test, WHO-developed, 10-item) and its short form AUDIT-C (3-item) are the dominant quantitative screening/phenotyping tools used both clinically and as the continuous phenotype in most large-scale genetic association studies; CAGE questionnaire is a simpler 4-item clinical screen.
Differential diagnosis: Other substance use disorders, primary mood/anxiety disorders (which can both cause and result from heavy drinking), and other causes of the downstream organ phenotypes (e.g., non-alcoholic fatty liver disease, viral hepatitis for liver findings; other causes of peripheral neuropathy/ataxia).

Screening

Universal primary-care screening with AUDIT-C is recommended by USPSTF for adults, followed by brief intervention/referral to treatment ("SBIRT" model) for those screening positive.

11. Outcome/Prognosis

Survival and mortality

AUD substantially elevates all-cause mortality, chiefly through liver disease (cirrhosis, hepatocellular carcinoma), cardiovascular disease, alcohol-related cancers (esophageal, liver, breast, colorectal — ethanol/acetaldehyde is an IARC Group 1 carcinogen), unintentional injury, and suicide. Age-standardized AUD-attributable mortality has declined globally from 1990–2021 even as absolute burden has risen with population growth (GBD trend analyses, PMC12336152).

Morbidity and functional outcomes

Substantial disability contribution captured in global DALY estimates; functional impairment spans occupational, relationship, cognitive (frontostriatal executive dysfunction persisting into abstinence in a subset of patients), and legal/financial domains. Quality-of-life measures (EQ-5D, SF-36) are consistently reduced in active AUD relative to the general population and improve, though often not fully normalize, with sustained remission.

Disease course / complications

Progressive liver disease (steatosis → hepatitis → fibrosis → cirrhosis → hepatocellular carcinoma), Wernicke-Korsakoff syndrome, cardiomyopathy, pancreatitis, peripheral neuropathy, immune suppression/infection susceptibility, and high rates of co-occurring psychiatric illness (below).

Psychiatric comorbidity (major prognostic driver)

Comorbid major depressive disorder, anxiety disorders (including generalized anxiety, panic, and especially social anxiety disorder — lifetime comorbidity with AUD ≈2.4% in the general population, with social anxiety disorder associated with OR≈2.8 for alcohol dependence and OR≈1.2 for alcohol abuse; PMC2917264), PTSD, and bipolar disorder are all substantially elevated among individuals with AUD (PMC7006178 review of psychiatric comorbidities in AUD).
Among individuals with alcohol-associated liver disease specifically, nationwide data (2015–2023) show significantly increased prevalence of MDD, anxiety, and PTSD in both cirrhotic and non-cirrhotic groups relative to the general population (Digestive Diseases and Sciences 2025 nationwide trend study).
Top physical comorbidities in treatment-seeking AUD populations include hypertension, asthma, dyslipidemia, and liver enzyme abnormalities (PMC8783789 pilot comorbidity study).

Prognostic factors

Earlier treatment engagement, milder baseline severity, absence of psychiatric comorbidity, strong social support, and abstinence-oriented treatment adherence predict better outcomes; conversely, comorbid psychiatric illness, severe dependence (high symptom count), early-onset drinking, and ongoing high-risk environmental exposure predict poorer prognosis and higher relapse risk.

12. Treatment

Pharmacotherapy (FDA-approved)

Three medications are FDA-approved specifically for AUD: 1. Naltrexone (oral, approved 1994; long-acting injectable/Vivitrol, approved 2006) — mu-opioid receptor antagonist; reduces heavy drinking and helps prevent return to heavy drinking after a lapse by blunting the reinforcing/rewarding effects of alcohol. NCIT: Pharmacotherapy (NCIT:C15986); therapeutic_agent naltrexone. 2. Acamprosate (Campral, approved 2004) — modulates glutamatergic/GABAergic balance (putative NMDA receptor modulation), normalizing the post-withdrawal hyperglutamatergic state; supports abstinence maintenance with modest effect size; dosed three times daily (2 tablets/dose). 3. Disulfiram (Antabuse) — irreversibly inhibits aldehyde dehydrogenase, so that alcohol consumption causes acetaldehyde accumulation and an aversive "disulfiram-ethanol reaction" (flushing, nausea, vomiting, headache, hypotension) — a deterrent/aversion-based mechanism rather than an anti-craving mechanism.

Off-label / commonly used pharmacotherapy

Topiramate (glutamate/GABA modulation), gabapentin (particularly for withdrawal-adjacent anxiety/insomnia and protracted abstinence symptoms), baclofen (GABA-B agonist, used especially in some European countries and in hepatically impaired patients).

Emerging / investigational pharmacotherapy

GLP-1 receptor agonists are an actively emerging investigational class: a phase 2 randomized clinical trial of once-weekly semaglutide in AUD (enrollment Sept 2022–Feb 2024) found that low-dose semaglutide reduced alcohol consumption in a laboratory self-administration paradigm and significantly reduced weekly alcohol craving relative to placebo over 9 weeks, though effects on other consumption measures were mixed (published JAMA Psychiatry-family journal, PMID: 39937469; PMC11822619). A more recent randomized, double-blind, placebo-controlled trial in patients with AUD and comorbid obesity (published in The Lancet, 2026) reported alcohol consumption reductions of over 70% after 26 weeks of semaglutide treatment. NIH-funded work has also shown that adding weekly GLP-1 therapy to cognitive behavioral therapy further reduces heavy drinking days. Mechanistically, GLP-1 receptor signaling in reward-circuit regions (VTA, nucleus accumbens) is hypothesized to blunt alcohol's dopaminergic reinforcing effects, paralleling the class's established appetite/reward-modulating action in obesity and other addictive behaviors. Other agents under investigation in the search results include lacosamide (sodium channel modulator), pitolisant (histamine H3 antagonist/inverse agonist), and N-acetylcysteine (antioxidant/glutamatergic modulation), the latter studied specifically in veterans with comorbid TBI.

Pharmacogenomics

CPIC has issued naltrexone pharmacogenomic guidance considering both pharmacodynamic (OPRM1 rs1799971/A118G) and pharmacokinetic (ADH, ALDH) genes. The OPRM1 G-allele has been associated with improved naltrexone response and lower relapse rates in some cohort/meta-analytic studies, but prospective genotype-stratified randomized trials and rigorous meta-analyses have failed to confirm a clinically actionable effect, and current evidence does not support routine clinical genotyping to guide naltrexone prescribing (PMC4165632; systematic review/meta-analysis literature on rs1799971).

Psychosocial/behavioral treatment

Cognitive behavioral therapy (CBT), motivational enhancement therapy, 12-step facilitation/mutual-help group participation (Alcoholics Anonymous), contingency management, and couples/family-based interventions are core evidence-based non-pharmacological treatments, often combined with pharmacotherapy for best outcomes (as illustrated by the CBT+GLP-1 combination trial above). NCIT: Behavioral Counseling / Therapeutic Procedure terms as available.

Withdrawal management (acute)

Benzodiazepines (the mainstay for withdrawal seizure/delirium tremens prevention) administered on a symptom-triggered or fixed-schedule protocol (e.g., CIWA-Ar scale-guided), supportive care, and thiamine repletion (to prevent/treat Wernicke encephalopathy) prior to glucose administration.

Treatment gaps and outcomes

Despite three FDA-approved medications, pharmacotherapy remains substantially underutilized in US treatment settings, and treatment response is heterogeneous — motivating the active pharmacogenomic and novel-mechanism (GLP-1, glutamatergic) research programs above.

13. Prevention

Primary prevention

Minimum legal drinking age laws, alcohol taxation/pricing policy, restriction of alcohol marketing/advertising (particularly targeting youth), outlet density regulation, school- and community-based prevention programs targeting delayed drinking onset, and parental monitoring interventions.

Secondary prevention (screening/early intervention)

Universal AUDIT-C screening in primary care with brief intervention and referral to treatment (SBIRT), USPSTF-recommended for all adults; early identification of hazardous/harmful use before progression to dependence.

Tertiary prevention

Relapse-prevention pharmacotherapy and behavioral maintenance treatment; management of comorbid psychiatric illness to reduce self-medication-driven relapse; thiamine supplementation in at-risk chronic drinkers to prevent Wernicke-Korsakoff progression; vaccination and infection-prevention counseling given AUD-associated immune suppression.

Genetic/risk counseling

While not a Mendelian disorder amenable to individual genetic counseling in the classical sense, family history discussion (given the well-established ~40–60% heritability) is a recognized part of risk communication in primary care and psychiatric practice, and population-level ALDH2/ADH1B genotype distribution informs public-health messaging in East Asian populations regarding flush-reaction and elevated esophageal cancer risk with continued heavy drinking despite the aversive reaction.

Public health

Policy-level interventions (minimum unit pricing, taxation, marketing restriction, drunk-driving law enforcement) have the strongest population-level evidence base among all prevention strategies for reducing AUD-attributable morbidity/mortality (WHO Global Status Report on Alcohol and Health framework).

14. Other Species / Natural Disease

AUD as clinically defined is a human diagnostic construct; however, alcohol-preference and alcohol-dependence-like phenotypes are extensively modeled and, to a lesser degree, observed naturalistically across species: - NCBI Taxon:9606 (Homo sapiens) — the disease itself. - No well-characterized naturally occurring veterinary/companion-animal AUD analog exists in the way that, e.g., diabetes or cancer have veterinary natural-disease counterparts (OMIA does not carry an AUD entry); alcohol-related pathology in other species is essentially always experimentally induced rather than naturally occurring. - Orthologous genes: ADH1B and ALDH2 orthologs are present and functionally conserved across mammals (mouse Adh1, Aldh2), underpinning the validity of rodent metabolic/behavioral models. - Comparative biology: The core mesocorticolimbic dopamine reward circuitry and its ethanol-responsive GABA/glutamate physiology are highly evolutionarily conserved from rodents to primates to humans, which is the biological basis for the strong translational utility of animal models (§15) despite AUD itself being a uniquely human diagnostic/behavioral construct. - Zoonotic potential: Not applicable.

15. Model Organisms

A broad and mechanistically informative set of model systems is used to dissect AUD biology (Cservenka & Ray review and others; PMC6683838 "Animal Models for the Genetic Study of Human Alcohol Phenotypes"; PMC11566292, 2024 review of genetic animal models for brain gene expression in AUD; translational review PMC/Nature Translational Psychiatry 2021):

Mammalian genetic/selectively-bred models

Selectively bred rat/mouse lines: High Alcohol Preference (HAP) and Low Alcohol Preference (LAP) mouse lines (bred from HS/Ibg founders; cHAP = crossed HAP replicate lines) and the classic alcohol-preferring (P) vs. non-preferring (NP) rat lines model genetic variation in voluntary alcohol consumption.
High Drinking in the Dark (HDID)-1 and HDID-2 mice: selectively bred over 20+ generations for reaching high blood alcohol concentrations in a binge-like "drinking in the dark" assay — models the binge-drinking phenotype specifically.
Knockout/transgenic/conditional models: Gene-targeted mice (e.g., Gabra2, Oprm1, Aldh2 knockouts/humanized alleles) used to causally test candidate genes identified in human GWAS; IMPC/KOMP/MGI-cataloged alcohol-related phenotyping data available for many such lines.
Non-human primates: Used for studies requiring closer translational fidelity to human social drinking patterns, voluntary chronic self-administration, and neuroimaging-comparable circuit studies.

Non-mammalian models

Zebrafish (Danio rerio): Increasingly used given transparent embryos enabling live anatomical/circuit characterization and high-throughput genetic screening of alcohol-response behavior.
Drosophila melanogaster: Shows conditioned place-preference-like responses to ethanol-paired cues and robust ethanol-induced behavioral sensitization/tolerance paradigms, exploiting powerful Drosophila genetic tools.
C. elegans: A genetically fully tractable invertebrate model with conserved ethanol-response pathways, used both for mechanistic dissection and for small-molecule/therapeutic screening (PMC/ScienceDirect C. elegans AUD therapeutics screening literature).

Model characteristics — phenotype recapitulation and limitations

Rodent models robustly recapitulate voluntary consumption, escape/withdrawal-associated hyperexcitability (tremor, seizure susceptibility), and core neurocircuit adaptations (mesolimbic dopamine blunting, glutamatergic sensitization) seen in human AUD. Limitations include the difficulty of modeling the complex, criterion-based DSM-5 psychiatric diagnosis (craving, social/role impairment) in non-verbal organisms, and cross-species differences in alcohol pharmacokinetics/metabolism rate that require careful dose calibration for translational validity — an important human-model-fidelity caveat analogous to the dismech schema's HUMAN_MODEL_MISMATCH discussion category, particularly relevant for translating rodent withdrawal-severity or craving-proxy behavioral assays to the human clinical phenotype.

Applications

These models collectively support dissection of genetic risk-locus function (knockout/humanized-allele validation of GWAS hits), neurocircuit-level mechanism (optogenetic/chemogenetic manipulation of VTA-NAc-amygdala-PFC circuitry), withdrawal pharmacology (benzodiazepine/anticonvulsant testing), and preclinical efficacy screening for novel pharmacotherapies (e.g., the preclinical GLP-1RA evidence base that motivated the semaglutide human trials in §12).

Resources

MGI, IMPC/KOMP (mouse gene-targeted lines and phenotyping), RGD (rat genomic resources for P/NP lines), ZFIN (zebrafish), FlyBase (Drosophila), WormBase (C. elegans), IMSR (strain repository).

Summary Table: Suggested Ontology Term Anchors for KB Curation

Table (click to expand)

Domain	Suggested term (verify CURIE via OAK/OLS before committing)
Disease	OMIM:103780; ICD-11 6C40 series; MONDO CURIE — unconfirmed, verify live
Causal/risk genes	HGNC:249 (ADH1B), HGNC:404 (ALDH2), HGNC:4083 (GABRA2), HGNC:24578 (KLB), HGNC:4196 (GCKR), HGNC:8156 (OPRM1)
Chemicals	CHEBI:16236 (ethanol), CHEBI:15343 (acetaldehyde)
Biological processes	GO:0006066 (alcohol metabolic process), GO:0035249 (glutamatergic synaptic transmission), GO:0051932 (GABAergic synaptic transmission)
Anatomy	UBERON terms for ventral tegmental area, nucleus accumbens, amygdala, prefrontal cortex, liver — verify exact CURIEs
Phenotypes	HP:0002378/HP:0030955 (tremor), HP:0002069 (generalized tonic-clonic seizure), HP:0001394 (cirrhosis), HP:0009830 (peripheral neuropathy), HP:0001397 (hepatic steatosis)
Treatment	NCIT:C15986 (Pharmacotherapy) + therapeutic_agent naltrexone/acamprosate/disulfiram/semaglutide; NCIT term for Behavioral Counseling

Key Gaps / Items Needing Further Verification Before KB Entry

Exact MONDO CURIE for alcohol use disorder/alcohol dependence — not confirmed via live ontology lookup in this pass; must be resolved via OLS/Monarch before curation to avoid a mismatched identifier.
Exact PMIDs for the Zhou et al. 2023 Nature Medicine multi-ancestry GWAS and the 2024 Nature Mental Health cross-disorder pleiotropy paper were not independently confirmed to the numeric PMID in this pass — the papers and journals are correctly identified, but curators should run just fetch-reference against the specific PMID before citing.
HPO coverage of AUD-specific behavioral/psychiatric criteria (craving, impaired control, social impairment) is sparse — HPO is built for somatic/syndromic phenotypes, so most DSM-5 AUD criteria will need to be captured as free-text/description content rather than forced HP term bindings; only the physiological/withdrawal and end-organ-complication phenotypes map cleanly to existing HP terms.
CL and UBERON exact CURIEs for brain reward-circuit cell types and regions listed above are given at the recall/best-estimate level and should be independently verified with runoak before use in a schema-bound annotation.